While it’s potentially promising, there’s not enough information yet to determine if the vaccine is safe and effective.
Rigor académico, oficio periodístico
Artículos sobre Clinical trials
Mostrando 41 - 60 de 208 artículos
Even if we came up with a definition of what makes the “best” vaccine, we don’t have the luxury of choice, when vaccines are in short supply.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
It was first officially described 115 years ago, but we still do not have a cure for Alzheimer’s disease. The human brain is extremely complex, and Alzheimer’s is its most complex disease.
With four COVID-19 vaccines approved for use in Canada, it’s time to answer FAQs about efficacy, immunity, eradication and variants.
A whistle-stop tour of the history of placebos.
We still don’t know if current vaccines prevent people from transmitting the virus to others. Here’s why that matters in 2021.
The reason the vaccine appears to have worked better in participants who initially received only half a dose is still somewhat of a mystery.
With COVID-19 vaccine announcements making headlines, non-scientists need to know what clinical trial results mean. Here are some key points to look for in vaccine trial reports.
Vaccines are being touted as taking seven to ten years to develop. But you shouldn’t be worried that COVID vaccines only took less than a year.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
The recent vaccine trial results certainly look impressive, but here’s how to fully interrogate what they mean.
Any COVID-19 vaccine is likely to be given first to higher risk groups before it is given to children. But we still need vaccines that are safe and effective for them too.
Pregnant women are at increased risk for serious COVID-19 complications and should be a high-priority group for vaccination. Excluding them from vaccine trials puts them and their offspring at risk.
There are many scientific and ethical challenges ahead. But these types of trials have helped in the development of vaccines against a few diseases. Could they do the same for COVID-19?
Australia’s contribution to the global COVAX initiative helps secure future vaccines. Here’s the full field of candidates.
Principales colaboradores
-
Professor and Director of the Stoneygate Centre for Excellence in Empathic Healthcare, University of Leicester
-
Professor and Director Academic Excellence, Macquarie University
-
Joel Lexchin es Amigo de The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Epidemiologist, Cochrane
-
Head of School and Dean of Pharmacy, University of Sydney
-
Professor of Immunology, RMIT University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Biostatistics and Epidemiology, University of South Australia
-
Professor of medicine, epidemiology & biostatistics, and philosophy, Western University
-
Head, Cancer Research Program, Monash University
-
Professor, School of Public Health, University of Gothenburg Sweden, University of the Witwatersrand
-
Researcher, L’Université d’Ottawa/University of Ottawa
-
Membre du comité d'éthique de l'Inserm, Inserm
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Professor of Medicine, Monash University
